Literature DB >> 10803530

Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?

B M Frost, G Gustafsson, R Larsson, P Nygren, G Lönnerholm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10803530     DOI： 10.1038/sj.leu.2401753

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group.

Authors:  Hiroaki Goto; Takeshi Inukai; Hiroyasu Inoue; Chitose Ogawa; Takashi Fukushima; Miharu Yabe; Akira Kikuchi; Kazutoshi Koike; Keitaro Fukushima; Keiichi Isoyama; Tomohiro Saito; Akira Ohara; Ryoji Hanada; Jiro Iwamoto; Noriko Hotta; Yoshihisa Nagatoshi; Jun Okamura; Masahiro Tsuchida
Journal:  Int J Hematol       Date:  2011-02-01       Impact factor: 2.490

2.  Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.

Authors:  Trudy D Buitenkamp; Ron A A Mathôt; Valerie de Haas; Rob Pieters; C Michel Zwaan
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

Review 3.  Clinical and biological aspects of myeloid leukemia in Down syndrome.

Authors:  Austin C Boucher; Kenneth J Caldwell; John D Crispino; Jamie E Flerlage
Journal:  Leukemia       Date:  2021-09-13       Impact factor: 12.883

4.  Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.

Authors:  Henrik Hasle; Ronald M Kline; Eigil Kjeldsen; Nik F Nik-Abdul-Rashid; Deepa Bhojwani; Jeffrey M Verboon; Stephanie P DiTroia; Katherine R Chao; Klas Raaschou-Jensen; Josefine Palle; C Michel Zwaan; Charlotte Guldborg Nyvold; Vijay G Sankaran; Alan B Cantor
Journal:  Blood       Date:  2022-05-26       Impact factor: 25.476

Review 5.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

6.  Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.

Authors:  Maureen M O'Brien; Jeffrey W Taub; Myron N Chang; Gita V Massey; Kimo C Stine; Susana C Raimondi; David Becton; Yaddanapudi Ravindranath; Gary V Dahl
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

Review 7.  Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors:  Ana C Xavier; Yubin Ge; Jeffrey W Taub
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

8.  The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.

Authors:  Y Ge; K M LaFiura; A A Dombkowski; Q Chen; S G Payton; S A Buck; S Salagrama; A E Diakiw; L H Matherly; J W Taub
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

9.  RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.

Authors:  Holly Edwards; Chengzhi Xie; Katherine M LaFiura; Alan A Dombkowski; Steven A Buck; Julie L Boerner; Jeffrey W Taub; Larry H Matherly; Yubin Ge
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

10.  Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia.

Authors:  Mariela Valle; Sharon E Plon; Karen R Rabin
Journal:  Leuk Res       Date:  2008-08-20       Impact factor: 3.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.